| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1439-0507.2002.TB04770.X |
| P698 | PubMed publication ID | 12690972 |
| P2093 | author name string | Groll AH | |
| P2860 | cites work | Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance P | Q24535844 |
| Azole cross-resistance in Aspergillus fumigatus | Q28345187 | ||
| Resistance to itraconazole in Aspergillus nidulans and Aspergillus fumigatus is conferred by extra copies of the A. nidulans P-450 14alpha-demethylase gene, pdmA. | Q30679946 | ||
| Acquired itraconazole resistance in Aspergillus fumigatus | Q32061952 | ||
| Itraconazole in cyclodextrin solution | Q33637258 | ||
| Amphotericin B with and without itraconazole for invasive aspergillosis: A three-year retrospective study | Q33719197 | ||
| Effects of the antifungal agents on oxidative drug metabolism: clinical relevance | Q33858325 | ||
| Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America | Q33894472 | ||
| Invasive mycoses in organ transplant recipients: controversies in prophylaxis and management | Q33933074 | ||
| Comparison of the E-test with the NCCLS M38-P method for antifungal susceptibility testing of common and emerging pathogenic filamentous fungi | Q33971884 | ||
| Interaction of common azole antifungals with P glycoprotein | Q34104641 | ||
| Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis | Q34111158 | ||
| Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo | Q34335230 | ||
| Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation | Q34417057 | ||
| Use of amphotericin B with azole antifungal drugs: what are we doing? | Q35117932 | ||
| Itraconazole for experimental pulmonary aspergillosis: comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasma | Q35821534 | ||
| Activities of an intravenous formulation of itraconazole in experimental disseminated Aspergillus, Candida, and Cryptococcus infections | Q39537321 | ||
| Efficacy of itraconazole solution in a rabbit model of invasive aspergillosis | Q39882453 | ||
| Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlle | Q40596481 | ||
| Cyclodextrins: their future in drug formulation and delivery | Q40895926 | ||
| Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization | Q41192883 | ||
| NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis | Q42599568 | ||
| Congestive heart failure associated with itraconazole | Q43638251 | ||
| Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. | Q43732838 | ||
| Caspofungin in combination with itraconazole for the treatment of invasive aspergillosis in humans | Q43933917 | ||
| An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group | Q44504692 | ||
| Adverse events associated with itraconazole in 189 patients on chronic therapy. | Q46013419 | ||
| Treatment of invasive aspergillosis with itraconazole | Q46380526 | ||
| Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID Mycoses Study Group criteria. | Q51193756 | ||
| Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukaemia. | Q54001854 | ||
| Hepatic injury associated with itraconazole. | Q55037189 | ||
| Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection | Q56837366 | ||
| In-vivo itraconazole resistance of Aspergillus fumigatus in systemic murine aspergillosis | Q59286608 | ||
| P921 | main subject | aspergillosis | Q259626 |
| P304 | page(s) | 48-55 | |
| P577 | publication date | 2002-01-01 | |
| P1433 | published in | Mycoses | Q1956531 |
| P1476 | title | Itraconazole--perspectives for the management of invasive aspergillosis | |
| P478 | volume | 45 Suppl 3 |
| Q46124302 | Central nervous system aspergillosis in an immunocompetent patient: cure in a hospice setting with very high-dose itraconazole |
| Q34680675 | Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model |
| Q44686777 | Invasive fungal infections in patients with hematologic malignancies: the next steps |
| Q80194579 | Itraconazole prophylaxis in pediatric cancer patients receiving conventional chemotherapy or autologous stem cell transplants |
| Q83821367 | Predictors of postoperative complications after radical resection for pulmonary aspergillosis |
| Q40153913 | Successful empirical antifungal therapy of intravenous itraconazole with pharmacokinetic evidence in pediatric cancer patients undergoing hematopoietic stem cell transplantation |
Search more.